Validation Data Gallery
|Positive WB detected in
|mouse brain tissue, fetal human brain tissue, rat brain tissue
|Positive IP detected in
|Positive IHC detected in
|human kidney tissue, rat kidney tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in
|Western Blot (WB)
|WB : 1:1000-1:4000
|IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
|IHC : 1:500-1:2000
|Flow Cytometry (FC)
|FC : 1:10-1:100
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
12617-1-AP targets GNAI1 in WB, IP, IHC, FC, ELISA applications and shows reactivity with human, mouse, rat samples.
|human, mouse, rat
|Host / Isotype
|Rabbit / IgG
|GNAI1 fusion protein Ag3290
|guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1
|Calculated molecular weight
|354 aa, 40 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
The guanine nucleotide-binding protein G(i), α-1 subunit (GNAI1), also known as Gαi-1, belongs to the Gαi family. GNAI1 is an adenylate cyclase inhibitor that modulates cAMP. GNAI1 exerts inhibitory effects on cAMP production through its interaction with GPCR and the inactivation of adenyl cyclase (PMID: 35678269). GNAI1 has 2 isoforms with molecular weights of 35 and 40 kDa, respectively.
|Product Specific Protocols
|WB protocol for GNAI1 antibody 12617-1-AP
|IHC protocol for GNAI1 antibody 12617-1-AP
|IP protocol for GNAI1 antibody 12617-1-AP
|FC protocol for GNAI1 antibody 12617-1-AP
|Click here to view our Standard Protocols
Drug Des Devel Ther
Network Pharmacology and Experimental Verification to Explore the Potential Mechanism of Yin-Huo-Tang for Lung Adenocarcinoma Recurrence.
Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance